Clinical trial · Observational
LUMINIST: LUng Cancer Molecular Insights Non Interventional Study
NCT02300831CI-TRIAL-00028639LUMINISTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recent development of therapies targeting specific biomarkers mutations is changing the standards of care and prognosis of patients with advanced NSCLC, but very few data are currently available on those emerging biomarkers. In addition, the correlation of biomarkers with patients' clinical outcomes in a standard of care setting is poorly understood. This study aims to address that need.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- NSCLC
- description
- The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
- interventionNames
- Other: Data Collection
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- Up to 34 months
- description
- The Overall Survival will be calculated from the first date of each line of therapy to end of follow-up or death, whichever occurs first.
Secondary outcomes (6)
- measure
- Progression Free survival (PFS)
- timeFrame
- Up to 34 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Provision of informed consent from the patient or next-of-kin for deceased patient at study entry, where this is mandated by local regulations 2. Female and male adults (according to each country regulations for age of majority) 3. Patients who are not eligible or choose not to enter selumetinib SELECT-1 or SELECT-2 trials 4. Patients with confirmed histological diagnosis of NSCLC Exclusion Criteria: 1\. Involved in the planning and/or conduct of this study (applies to both AZ staff and/or staff at the study site)
References
Publications (0)
Data not yet available
No reference posted for this study.